27.04 0.00 (0.00%)
After hours: 4:07PM EDT
|Bid||23.40 x 800|
|Ask||29.74 x 800|
|Day's Range||26.58 - 27.25|
|52 Week Range||21.30 - 29.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Abiomed (ABMD) is strategically focused on the market penetration of the company’s family of Impella heart pumps. The Impella device portfolio consists of Impella 2.5, Impella CP, Impella RP, Impella LD, and Impella 5.0 devices. To this end, Abiomed discontinued the sale of its AB5000 device used for heart surgery.
Abiomed (ABMD) is a supplier of mechanical circulatory support devices and offers a continuum of care to heart failure patients. Abiomed develops, manufactures, and commercializes products designed to improve the blood flow and perform the pumping function of the heart. Of the ten analysts covering Abiomed (ABMD) in February 2018, five analysts have given the stock a “strong buy” rating, three analysts have given it a “buy” rating, while two analysts have given it a “hold” rating.
At present, in-center hemodialysis is the predominant ESRD (end stage renal disease) therapy in the United States. According to NxStage Medical (NXTM), ~10%–15% of ESRD patients in the United States would be appropriate candidates for the company’s home dialysis equipment, System One. According to Centers for Medicare and Medicaid (or CMS), only 18% of dialysis clinics in the United States actively offer home hemodialysis for patients, and only 27% are certified to offer this therapy.
Since its inception, NxStage Medical (NXTM) has focused on creating a long-term sustainable model driven by innovative technologies. Although NxStage Medical has witnessed revenue growth, it has historically operated at a net loss. It expects the operating income it generates from its products business to continue to be offset by the losses in its kidney care business and the costs associated with its merger with Fresenius Medical Care Holdings (FAS).
Headquartered in Lawrence, Massachusetts, NxStage Medical (NXTM) is a medical technology company with a focus on developing, manufacturing, and marketing innovative products targeted at patients suffering from chronic or acute kidney failure. The company also operates NxStage kidney care dialysis centers, which treat end-stage renal disease (or ESRD) patients. NxStage Medical’s primary product is System One, which is capable of delivering the therapeutic flexibility and clinical benefits of traditional dialysis machines in a smaller, portable, and easy-to-use format.
Categories: Yahoo FinanceGet free summary analysis NxStage Medical, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of NxStage Medical, Inc. – Rockwell Medical, Inc., Fresenius Medical Care AG & Co. KGaA Sponsored ADR, Cantel Medical Corp., C. R. Bard, Inc., Baxter International Inc., Nephros, Inc., ... Read more (Read more...)
The top U.S. antitrust regulator has sent a chilling message to dealmakers with his opposition to AT&T Inc buying Time Warner Inc: Companies do not have to be competitors for their merger to hurt competition, and there are no simple fixes to get such deals approved. The Department of Justice's lawsuit to block the AT&T purchase could be a negative sign for other so-called "vertical" mergers - where the companies do not compete but one supplies the other - such as pharmacy operator CVS Health Corp's plan to buy insurer Aetna Inc. Investors had thought AT&T's acquisition of Time Warner, if not a slam dunk, would be approved by the Justice Department and its antitrust division chief Makan Delrahim with relatively few asset sales or conditions.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NxStage Medical, Inc. Here are 5 ETFs with the largest exposure to NXTM-US. Comparing the performance and risk of NxStage Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)